Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease-Reference-Cited by-同舟云学术

Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease

Published:2018-12-21 Issue:6 Volume:9 Page:
ISSN:2161-2129
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Montoya Marhiah C.¹²³,Krysan Damian J.²³

Affiliation:

1. Clinical and Translational Science Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

2. Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

3. Department of Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

Abstract

The concept of repurposing previously approved medications to the treatment of new indications by taking advantage of off-target effects has gained traction in recent years, particularly in areas of medicine that do not offer large profits to pharmaceutical firms. As infectious disease discovery research has declined among large pharmaceutical companies, the potential payoff of repurposing has become attractive.

Funder

National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.02272-18

Reference80 articles.

1. The future of drug repositioning: old drugs, new opportunities;Doan TL;Annu Rep Med Chem,2011

2. Drug repositioning: identifying and developing new uses for existing drugs

3. A review of thalidomide’s history and current dermatological applications;Perri AJ;Dermatol Online J,2003